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uncertain. Furthermore, there is no evidence that triglycerides or free fatty acids directly
impair vascular function as opposed to reflex or hormonal changes induced following
systemic exposure.
Methods: We tested the hypothesis that local HTG impairs resistance vessel endothelial
function, by examining whether forearm blood flow (FBF) responses to intra-arterial ace-
tylcholine (Ach), bradykinin (BK), and nitroprusside were altered by coinfusion of
intralipid (IL 200 mg/min) for 90 min in 10 healthy adults; age 39±4, 7M.
Results: IL increased plasma triglycerides from 80±20 to 433±62 and free fatty acids
from 0.5±0.1 to 1.9±0.2 (p=0.0003 for both). Forearm vasodilatation to Ach (p=0.83), BK
(p=0.73), and nitroprusside (p=0.34) were not reduced by HTG (figure).
Conclusion: Local HTG sustained for >90 min does not impair resistance vessel endot-
helial function. These results suggest that resistance vessels are less susceptible to the
deleterious effects of triglycerides than conduit vessels. Alternatively, the vascular effects
of systemic HTG may be mediated indirectly, perhaps via hormonal or reflex mecha-
nisms.
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1160-165 Angiotensin II Receptor 1 Blocker Improves Not Only 
Hypertension but Also Ventricular Arrhythmogenicity
Chikashi Suga, Kazuo Matsumoto, Ritsushi Kato, Toshimasa Tosaka, Atsushi Sakamoto, 
Madoka Nozawa, Yurika Hotta, Osami Komoto, Shigeyuki Nishimura, Hiroshi Suga, 
Saitama Medical School, Saitama, Japan, Suga Clinic, Saitama, Japan
Background: Angiotensin II receptor 1 blocker (ARB) has been proven to improve car-
diovascular mortality and morbidity. However, the influence of ARB on fatal arrhythmia
remained unknown. The purpose of this study was to evaluate if ARB has any beneficial
effect on ventricular arrhythmogenicity, and also if the effect is associated with the
decrease of blood pressure.
Methods: This study consists of 69 patients (30 males, mean age 63.8±10 years) with
hypertension in whom valsartan was administrated from February 2001 to May 2002. We
assessed mean blood pressure (MBP), RV5+SV1 on ECG, QT dispersion (QTD) and QTc
dispersion (QTcD) before and 10 months later of introduction of valsartan administration.
We also assessed correlation between the difference of QTD or QTcD before and 10
month later of the valsartan administration and the difference of MBP or RV5+SV1 before
and 10 month later of the valsartan administration.
Results: MBP (119.9±12.1mmHg vs. 101.9±10.6mmHg, p<0.0001), QTD
(60.3±16.8msec vs. 47±11.3msec, p<0.0001) and QTcD (62.6±17.1msec vs.
49.3±12.6msec, p<0.0001) except RV5+SV1 (2.62±1.09mV vs. 2.53±0.98mV, NS) signifi-
cantly decreased through the study period. There was no significant correlation between
the difference of QTD or QTcD before and 10 month later of the valsartan administration
and the difference of MBP or RV5+SV1 before and 10 month later of the valsartan admin-
istration.
Conclusion: QTD and QTcD decreased after valsartan administration. The decrease of
QTD and QTcD did not correlate with the change of blood pressure or RV5+SV1. Thus, it
is suggested that valsartan might have beneficial effect on ventricular arrhythmogenicity
that could not be explained by the improvement of hypertension or left ventricular hyper-
trophy.
1160-166 C-Type Natriuretic Peptide Improves Left Ventricular 
Performance at Rest and During Exercise After Heart 
Failure
Hiroshi Hasegawa, Atsushi Morimoto, Heng-Jie Cheng, William C. Little, Che-Ping 
Cheng, Wake Forest University School of Medicine, Winston-Salem, NC
Background. The diastolic dysfunction present at rest is exacerbated during exercise
(Ex) in heart failure (CHF). C-type natriuretic peptide (CNP), the third member of the
natriuretic peptide family with vasodilating, natriuretic, and lusitropic actions, may prevent
this abnormal Ex response after CHF.
Methods. We assessed the effects of CNP on left ventricular (LV) systolic and diastolic
performance at rest and during submaximum Ex (3.5-5.5 mph for 5-8 min) in 8 chroni-
cally instrumented dogs with pacing-induced CHF. Since CNP mediated its biological
actions via cGMP, we also measured plasma cGMP levels in response to CNP infusion at
rest before and after CHF.
Results. CNP (2 µg/kg plus 0.4 µg/kg/min, iv, 20 min) caused a similar increase in cGMP
levels before (7.7±4.4 to 29.4±5.7 pmol/ml) and after CHF (27.7±4.4 to 69.4±5.7 pmol/
ml). At rest, treatment with CNP produced reductions in LV end-systolic pressure (PES,
92±10.8 vs 102±12.1 mmHg), arterial elastance (EA, 8.6±1.2 vs 12.2±1.4 mmHg/ml) and
end-diastolic pressure (PED, 38.4±4 vs 43.2±6 mmHg) (p<0.05). The peak mitral flow
(dV/dtmax, 198±59 vs 164±38 ml/sec) was also increased due to decreases in minimum
LVP (LVPmin, 18.6±6.7 vs 23.3±6.3 mmHg) and the time constant of LV relaxation (τ,
41±7 vs 46±7 msec) (p<0.05). In addition, the slope of LV end-systolic pressure-volume
relations (EES) produced by caval occlusion was also increased (5.4±0.6 vs 4.1±0.5
mmHg/ml). The LV-arterial (A) coupling (C), quantified as EES/EA, was improved
(0.68±0.20 vs 0.49±0.18) (p<0.05). The beneficial effects persisted during Ex after CHF.
At matched levels of Ex, treatment with CNP tolerated Ex-induced increases in PES (∆P=
3.3±0.2 vs 7.3±0.4 mmHg), mean LAP (∆P= -3.2±2.6 vs 3.1±2.7 mmHg), and LVPmin
(∆P= -3.4±1.2 vs 1.3±1.0 mmHg) (p<0.05). With CNP, τ was much shortened (∆= -
0.6±4.0 vs 2.9±3.7 ms), and peak mitral flow
 
was further augmented (∆dV/dtmax, 71±23
vs 41±12 ml/sec) (p<0.05).
Conclusion. After CHF, the generation of cGMP in response to CNP is not blunted. CNP
produces arterial vasodilatation and augments LV relaxation, diastolic filling and LV arte-
rial coupling, thus improving LV performance, both at rest and during Ex after CHF.
1160-167 Defining the Acute Cardiorenal Response to High Dose 
Nesiritide in Severe Experimental Congestive Heart 
Failure
John A. Schirger, Alessandro Cataliotti, Horng H. Chen, Guido Boerrigter, Lisa C. 
Costello-Boerrigter, Fernando L. Martin, Gail J. Harty, John C. Burnett, Jr., Mayo Clinic, 
Rochester, MN
Background: Previous human studies report improved cardiac filling pressures and glo-
bal clinical status in acute decompensated congestive heart failure (CHF) using human
brain natriuretic peptide (BNP)/Nesiritide. Severe CHF however may be associated with
emergence of reduced sensitivity to BNP due to receptor down-regulation, enhanced
degradation or reduced renal perfusion pressure. We investigated the effects of clinical
and high dose IV Nesiritide on systemic hemodynamics, renal function, and sodium
excretion in severe canine CHF, hypothesizing that supraclinical doses further reduce
cardiac filling pressures and enhance sodium excretion without marked hypotension.
Methods: We used an established model of pacing induced (240 bpm, 10 days) severe
canine (n=7) CHF characterized by decreased cardiac output, increased cardiac filling
pressures, sodium retention and neurohumoral activation. After a baseline clearance IV
Nesiritide was infused with a lead in period followed by 30 minute clearances at doses of
100 (approximating doses in clinical trials) and 1000 ng/kg/min (10 fold greater than clini-
cal trials).
Results: Clinical dosing decreased pulmonary capillary wedge pressure (PCWP) (23±1
vs 18±1 mmHg, p<0.05), pulmonary artery pressure (PAP) (31±3 vs 27±2 mmHg,
p<0.05), and mean arterial pressure (MAP) (105±4 vs 87±4 mmHg, p<0.05), and tended
to increase cardiac output (CO) (1.43±0.21 vs 1.91±0.39 L/min) vs baseline. High dose
IV Nesiritide further deceased PCWP (17+2 mmHg, p<0.05) and PAP (25±1 mmHg,
p<0.05), without further decreasing MAP, and tended to further increase CO. Importantly,
glomerular filtration rate tended to increase compared to baseline (26±5 L/min) with both
clinical (41±10 L/min) and high (48±15 L/min) doses of IV Nesiritide. Urinary sodium
excretion tended to increase at clinical dosing (7±4 µEq/min)and significantly increased
(12±6 µEq/min, p<0.05) with high dose IV Nesiritide vs baseline (2± 0.4 µEq/min) in the
absence of further decreases in MAP.
Conclusion: These studies in experimental CHF suggest it may be possible to increase
the dosing of IV Nesiritide, thus warranting carefully designed future human investiga-
tions in severe CHF.
1160-168 The Estrogen-Induced Alterations in Arterial Stiffness 
are Independent of the Non-Dipping Status but 
Attenuated by Progesterone in Hypertensive 
Postmenopausal Women
C. Tsioufis, K. Tzioumis, A. Hatziyianni, K. Dimitriadis, E. Taxiarchou, D. Hatzis, C. 
Stefanadis, I. Kallikazaros, P. Toutouzas, Athens Univeristy, Athens, Greece, 
Hippokration Hospital, Athens, Greece
Background: Large artery stiffness and attenuated nocturnal blood pressure (BP) fall are
associated with unfavorable cardiovascular outcome, in essential hypertension. We
assessed the hypothesis that the addition of progesterone and the absence of normal cir-
cadian BP variation may modify the beneficial effects of hormonal replacement therapy
(HRT) on large artery distensibility in hypertensive postmenopausal women.
Methods: For this purpose, we studied aortic stiffness in 56 postmenopausal women
(aged 52 years, 3.4 years after menopause) with untreated, mild essential hypertension
randomized to conjugated estrogen alone (n=20), estrogen plus medroxyprogesterone
(n=20) or placebo (n=16). Aortic elasticity was evaluated, non-invasively, on the basis of
pulse wave velocity (PWV) measurements at baseline and at 12 weeks after treatment.
At baseline, women receiving conjugated estrogen alone, underwent 24h ambulatory BP
monitoring and were classified to non-dippers (defined by a reduction in the night mean
systolic and diastolic BP <10% from day values) (n=7) and dippers (the remaining sub-
jects) (n=13).
Results: In the entire study population office BP was 146/93 mmHg and left ventricular
mass index was 104±26 gr/m2. The patients’ groups were matched for age, time since
menopause, smoking status, office blood pressure and PWV values at baseline. At 12
weeks of treatment, in women receiving estrogen alone, aortic PWV was significantly
reduced (6.31 vs 6.09 m/sec, p<0.005), while in those receiving combined HRT or pla-
cebo, PWV did not change (6.32 vs 6.28 and 6.33 vs 6.30 m/sec, respectively, p=NS for
both cases). Treatment with conjugated estrogen induced a significant reduction in aortic
PWV in both groups of dippers and non-dippers, after 12 weeks. Furthermore, the
degree of reduction in PWV did not differ in dippers (by 0.27 m/sec) and non-dippers (by
